US5217996A
(en)
*
|
1992-01-22 |
1993-06-08 |
Ciba-Geigy Corporation |
Biaryl substituted 4-amino-butyric acid amides
|
IL115995A0
(en)
*
|
1994-11-15 |
1996-01-31 |
Bayer Ag |
Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
|
TR199700834T1
(xx)
*
|
1995-02-22 |
1998-01-21 |
Novartis Ag |
1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
|
MY132550A
(en)
|
1996-08-22 |
2007-10-31 |
Novartis Ag |
Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
|
IL144285A0
(en)
*
|
1999-03-29 |
2002-05-23 |
Bristol Myers Squibb Co |
Pharmaceutical compositions containing a vasopeptidase inhibitor
|
US7468390B2
(en)
*
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
CN1615134A
(zh)
*
|
2002-01-17 |
2005-05-11 |
诺瓦提斯公司 |
含有缬沙坦和nep抑制剂的药物组合物
|
GB0203061D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE550656T1
(de)
*
|
2003-08-20 |
2012-04-15 |
Alere San Diego Inc |
Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
|
US7868037B2
(en)
*
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7781478B2
(en)
*
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7772271B2
(en)
*
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US8013006B2
(en)
*
|
2004-07-14 |
2011-09-06 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
MX2007000762A
(es)
|
2004-07-22 |
2007-04-02 |
Ptc Therapeutics Inc |
Tienopiridinas para tratamientode hepatitis c.
|
MY146830A
(en)
*
|
2005-02-11 |
2012-09-28 |
Novartis Ag |
Combination of organic compounds
|
WO2007045663A2
(en)
*
|
2005-10-19 |
2007-04-26 |
Novartis Ag |
Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
EP1903027A1
(en)
*
|
2006-09-13 |
2008-03-26 |
Novartis AG |
Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
|
JP5715339B2
(ja)
*
|
2007-01-12 |
2015-05-07 |
ノバルティス アーゲー |
5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
TWI448284B
(zh)
*
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
EP2200975A1
(en)
|
2007-09-07 |
2010-06-30 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
AU2008307798B2
(en)
*
|
2007-10-05 |
2013-10-03 |
Verastem, Inc. |
Pyrimidine substituted purine derivatives
|
US8212052B2
(en)
*
|
2007-12-11 |
2012-07-03 |
Theravance, Inc. |
Dual-acting benzoimidazole antihypertensive agents
|
AU2012202949B2
(en)
*
|
2008-01-17 |
2015-01-22 |
Novartis Ag |
Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
|
PE20091364A1
(es)
*
|
2008-01-17 |
2009-10-13 |
Novartis Ag |
Proceso para la preparacion de inhibidores de nep
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
CN101607875B
(zh)
*
|
2008-06-17 |
2012-07-25 |
中国石油化学工业开发股份有限公司 |
制造环烷酮的方法
|
EP2334651A2
(en)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101774941A
(zh)
*
|
2009-01-13 |
2010-07-14 |
浙江九洲药业股份有限公司 |
2-酰基氨基-3-联苯基丙酸的制备及拆分方法
|
EP2434895A4
(en)
|
2009-05-13 |
2013-08-07 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
ME01923B
(me)
*
|
2009-05-28 |
2015-05-20 |
Novartis Ag |
Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
|
MX2011012627A
(es)
*
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
|
ES2611107T3
(es)
|
2009-07-07 |
2017-05-04 |
Theravance Biopharma R&D Ip, Llc |
Agentes antihipertensivos de pirazol, de doble acción
|
WO2011011232A1
(en)
|
2009-07-22 |
2011-01-27 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
US8481549B2
(en)
|
2010-01-19 |
2013-07-09 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
ES2550485T3
(es)
*
|
2010-01-22 |
2015-11-10 |
Novartis Ag |
Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos
|
PL2609075T3
(pl)
|
2010-08-23 |
2016-09-30 |
|
Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP
|
CN103080072B
(zh)
|
2010-08-23 |
2016-03-16 |
诺华有限公司 |
制备可用于生产nep抑制剂的中间体的新方法
|
MA34483B1
(fr)
|
2010-08-24 |
2013-08-01 |
Novartis Ag |
Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
|
US8993631B2
(en)
*
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
ME02295B
(me)
|
2010-12-15 |
2016-02-20 |
Theravance Biopharma R&D Ip Llc |
Inhibitori neprilizina
|
MX354476B
(es)
|
2010-12-15 |
2018-03-07 |
Theravance Inc |
Inhibidores de neprilisina.
|
EP2675792B1
(en)
|
2011-02-17 |
2016-01-06 |
Theravance Biopharma R&D IP, LLC |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
WO2012112742A1
(en)
|
2011-02-17 |
2012-08-23 |
Theravance, Inc. |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
CA2835220A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
CN103596928B
(zh)
|
2011-05-31 |
2017-02-15 |
施万生物制药研发Ip有限责任公司 |
脑啡肽酶抑制剂
|
ES2642883T3
(es)
|
2011-05-31 |
2017-11-20 |
Theravance Biopharma R&D Ip, Llc |
Inhibidores de neprilisina
|
TWI560172B
(en)
|
2011-11-02 |
2016-12-01 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
AR089955A1
(es)
*
|
2012-02-15 |
2014-10-01 |
Theravance Inc |
Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
|
CA2871292A1
(en)
|
2012-05-31 |
2013-12-05 |
Theravance Biopharma R&D Ip, Llc |
Nitric oxide donor neprilysin inhibitors
|
PL2864292T3
(pl)
|
2012-06-08 |
2017-10-31 |
Theravance Biopharma R&D Ip Llc |
Inhibitory neprylizyny
|
CN104470521B
(zh)
|
2012-06-08 |
2017-04-12 |
施万生物制药研发Ip有限责任公司 |
脑啡肽酶抑制剂
|
RS55797B1
(sr)
|
2012-08-08 |
2017-08-31 |
Theravance Biopharma R&D Ip Llc |
Inhibitori neprilizina
|
WO2014029848A1
(en)
|
2012-08-24 |
2014-02-27 |
Novartis Ag |
Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
|
TR201808541T4
(tr)
|
2013-02-14 |
2018-07-23 |
Novartis Ag |
Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
|
MX2015010434A
(es)
|
2013-02-14 |
2015-10-05 |
Novartis Ag |
Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
US8901169B2
(en)
|
2013-03-05 |
2014-12-02 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
CN104230865B
(zh)
*
|
2013-06-13 |
2018-01-09 |
上海翰森生物医药科技有限公司 |
联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
|
WO2015028941A1
(en)
|
2013-08-26 |
2015-03-05 |
Novartis Ag |
New use
|
EP3038653A1
(en)
|
2013-08-26 |
2016-07-06 |
Novartis AG |
New use
|
WO2015116760A1
(en)
|
2014-01-30 |
2015-08-06 |
Theravance Biopharma R&D Ip, Llc |
5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
|
US9593110B2
(en)
|
2014-01-30 |
2017-03-14 |
Theravence Biopharma R&D IP, LLC |
Neprilysin inhibitors
|
CN106795099B
(zh)
*
|
2014-04-10 |
2019-11-26 |
南京奥昭生物科技有限公司 |
用于治疗高血压和心血管疾病的前药和组合物
|
JP6591530B2
(ja)
|
2014-08-07 |
2019-10-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
CN105461587A
(zh)
*
|
2014-08-27 |
2016-04-06 |
上海翰森生物医药科技有限公司 |
Ahu-377半钙盐晶型及其制备方法和应用
|
CN105622452A
(zh)
*
|
2014-08-27 |
2016-06-01 |
上海翰森生物医药科技有限公司 |
Ahu-377结晶型游离酸及其制备方法和应用
|
CN105367438A
(zh)
*
|
2014-08-27 |
2016-03-02 |
上海翰森生物医药科技有限公司 |
AHU-377α-苯乙胺盐多晶型及其制备方法和应用
|
WO2016029828A1
(zh)
*
|
2014-08-27 |
2016-03-03 |
上海翰森生物医药科技有限公司 |
AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
|
WO2016037098A1
(en)
|
2014-09-04 |
2016-03-10 |
Concert Pharmaceuticals, Inc. |
Deuterated sacubitril
|
PL3218351T3
(pl)
|
2014-11-14 |
2019-12-31 |
Zentiva K.S. |
Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
|
CN105693543B
(zh)
*
|
2014-12-15 |
2018-08-10 |
四川海思科制药有限公司 |
沙库比曲类衍生物、其药物组合物、制备方法及用途
|
CN104557600B
(zh)
*
|
2015-01-26 |
2016-05-04 |
苏州明锐医药科技有限公司 |
沙库比曲的制备方法
|
MY187899A
(en)
|
2015-02-11 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
(2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
|
TW201632493A
(zh)
|
2015-02-13 |
2016-09-16 |
諾華公司 |
新穎方法
|
MY191183A
(en)
|
2015-02-19 |
2022-06-04 |
Theravance Biopharma R&D Ip Llc |
(2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
|
WO2016135751A1
(en)
|
2015-02-25 |
2016-09-01 |
Mylan Laboratories Limited |
Novel process for the preparation of sacubitril and its intermediates
|
CN105963296B
(zh)
*
|
2015-03-12 |
2020-01-21 |
深圳信立泰药业股份有限公司 |
一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
|
AU2016236659B9
(en)
*
|
2015-03-20 |
2019-05-02 |
Crystal Pharmatech Co., Ltd. |
AHU377 crystal form, preparation method and use thereof
|
PT3294283T
(pt)
|
2015-05-11 |
2023-06-07 |
Novartis Ag |
Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
|
WO2016193883A1
(en)
|
2015-05-29 |
2016-12-08 |
Novartis Ag |
Sacubitril and valsartan for treating metabolic disease
|
CN104860894B
(zh)
*
|
2015-06-10 |
2017-05-17 |
北京博全健医药科技有限公司 |
一种抗心衰药lcz696的制备方法
|
KR20200117037A
(ko)
*
|
2015-06-12 |
2020-10-13 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
삼나트륨 발사르탄:사쿠비트릴의 고체 형태
|
WO2016203500A2
(en)
|
2015-06-19 |
2016-12-22 |
Actavis Group Ptc Ehf. |
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
SI3317248T1
(sl)
|
2015-07-02 |
2021-01-29 |
Novartis Ag |
Sakubitril kalcijeve soli
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
WO2017009784A1
(en)
|
2015-07-14 |
2017-01-19 |
Cadila Healthcare Limited |
Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
|
WO2017012600A1
(en)
|
2015-07-20 |
2017-01-26 |
Zentiva, K.S. |
A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
|
JP6849618B2
(ja)
|
2015-07-23 |
2021-03-24 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
中性エンドペプチダーゼの阻害剤(NEP阻害剤)および/またはアンジオテンシンII拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ(sGC)の刺激薬および/または活性化薬ならびにその使用
|
WO2017029261A1
(de)
*
|
2015-08-19 |
2017-02-23 |
Bayer Pharma Aktiengesellschaft |
Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
|
WO2017033128A1
(en)
|
2015-08-25 |
2017-03-02 |
Novartis Ag |
Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
|
JP6598985B2
(ja)
|
2015-08-28 |
2019-10-30 |
ノバルティス アーゲー |
新規の使用
|
WO2017051326A1
(en)
|
2015-09-23 |
2017-03-30 |
Novartis Ag |
New processes and intermediates useful in synthesis of nep inhibitors
|
WO2017072636A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical synergistic combination
|
US10377697B2
(en)
|
2015-12-10 |
2019-08-13 |
Novartis Ag |
Process and intermediates
|
EP3386945A1
(en)
*
|
2015-12-11 |
2018-10-17 |
Zentiva, K.S. |
Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
|
CN106977417A
(zh)
*
|
2016-01-15 |
2017-07-25 |
常州方楠医药技术有限公司 |
一种沙库比曲钠盐的晶型及其制备方法
|
KR20180103940A
(ko)
|
2016-02-03 |
2018-09-19 |
노파르티스 아게 |
유기 화합물의 갈레닉(Galenic) 제제
|
KR20180114225A
(ko)
|
2016-03-08 |
2018-10-17 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
(2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
CN105753733B
(zh)
*
|
2016-04-15 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
Ahu377的晶型及其制备方法与用途
|
CN105820064A
(zh)
*
|
2016-04-18 |
2016-08-03 |
浙江天宇药业股份有限公司 |
一种联苯基丙氨醇衍生物的合成方法及中间体
|
WO2017191620A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Sun Pharmaceutical Industries Limited |
A crystalline form of a salt of sacubitril and a process of its preparation
|
US20190256454A1
(en)
|
2016-07-05 |
2019-08-22 |
Novartis Ag |
New process for early sacubitril intermediates
|
CN107602399B
(zh)
*
|
2016-07-11 |
2020-09-25 |
江西东邦药业有限公司 |
一种脑啡肽酶抑制剂中间体的制备方法
|
WO2018033866A1
(en)
|
2016-08-17 |
2018-02-22 |
Novartis Ag |
New processes and intermediates for nep inhibitor synthesis
|
CN106318988B
(zh)
*
|
2016-08-23 |
2020-11-03 |
迪嘉药业集团有限公司 |
一种lcz696关键中间体的制备方法
|
US10683260B2
(en)
|
2016-09-07 |
2020-06-16 |
Nanjing Noratech Pharmaceuticals Co., Ltd. |
Crystalline form of sacubitril sodium salt
|
CN106478437A
(zh)
*
|
2016-09-27 |
2017-03-08 |
南通常佑药业科技有限公司 |
一种γ‑氨基戊酸酯衍生物的制备方法
|
CN106496055A
(zh)
*
|
2016-10-09 |
2017-03-15 |
杭州科巢生物科技有限公司 |
一种抗心衰新药的关键组分沙库比曲的新合成方法
|
WO2018069833A1
(en)
*
|
2016-10-10 |
2018-04-19 |
Laurus Labs Limited |
Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
|
KR20190077467A
(ko)
|
2016-10-28 |
2019-07-03 |
바이오콘 리미티드 |
비정질 삼나트륨 사쿠비트릴 발사르탄 및 이의 제조방법
|
EP3558930B1
(en)
|
2016-12-23 |
2021-05-26 |
Novartis AG |
New process for early sacubitril intermediates
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
CN106831473B
(zh)
*
|
2017-02-22 |
2019-07-16 |
江西瑞雅药业有限公司 |
3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
|
WO2018178295A1
(en)
|
2017-03-31 |
2018-10-04 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Stable hot-melt extrudate containing valsartan and sacubitril
|
WO2019020706A1
(en)
|
2017-07-28 |
2019-01-31 |
Synthon B.V. |
PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
|
EP3694493A1
(en)
|
2017-10-13 |
2020-08-19 |
Alfred E. Tiefenbacher (GmbH & Co. KG) |
Tablet containing valsartan and sacubitril
|
WO2019127994A1
(zh)
*
|
2017-12-27 |
2019-07-04 |
浙江天宇药业股份有限公司 |
一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
|
US11839614B2
(en)
|
2018-01-31 |
2023-12-12 |
Intra-Cellular Therapies, Inc. |
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201810326D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Johnson Matthey Plc |
Crystalline form of sacubitril, its preparation and use
|
WO2020039386A1
(en)
|
2018-08-23 |
2020-02-27 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN109503404A
(zh)
*
|
2018-12-28 |
2019-03-22 |
凯瑞斯德生化(苏州)有限公司 |
一种lcz-696关键中间体的制备方法
|
CN110128298B
(zh)
*
|
2019-06-13 |
2021-08-03 |
南京一心和医药科技有限公司 |
一种沙库巴曲中间体的合成方法
|
CN113135836A
(zh)
*
|
2020-01-20 |
2021-07-20 |
鲁南制药集团股份有限公司 |
一种沙库巴曲钙盐的制备方法
|
CN111253425B
(zh)
*
|
2020-02-21 |
2022-04-29 |
常州南京大学高新技术研究院 |
一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
|
JP7064527B2
(ja)
*
|
2020-05-01 |
2022-05-10 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
CN112661671B
(zh)
*
|
2020-12-22 |
2022-04-22 |
江苏阿尔法药业股份有限公司 |
一种沙库巴曲中间体的制备方法
|
WO2022224274A1
(en)
|
2021-04-20 |
2022-10-27 |
Mylan Laboratories Limited |
Polymorphic forms of sacubitril-telmisartan (1:1)
|